Prevalence of Frailty Among People Aged 75 and Over Living at Home (FRAIL-DOM)
March 9, 2022 updated by: Université de Reims Champagne-Ardenne
The aging of population lead to study ways to prevent dependence. Frailty is a precursor to dependence which can be reversible. In the literature, estimate of prevalence of frailty is highly variable depending on the frailty definition, the population studied and the screan tool used. In fact, many scales to measure frailty have emerged without gold standard.
The SEGAm showed its usefulness in aged patients living at home.
Study Overview
Detailed Description
The aim of the study is to describe prevalence of frailty in patients aged of 75 and more living at home.
Study Type
Observational
Enrollment (Actual)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Grand-Est
-
Bar-sur-Seine, Grand-Est, France, 10110
- Maison de Santé Pluridisciplinaire de Bar sur Seine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
75 years and older (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
patients aged of 75 and more living at home
Description
Inclusion Criteria:
- male or female
- aged of 75 and more
- living at home
- agreeing to participate in the study
Exclusion Criteria:
- none
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
aged of 75 and more living at home
aged of 75 and more living at home" group: patients aged of 75 and more living at home
|
frailty evaluation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frailty
Time Frame: Day 0
|
Frailty evaluated using SEGA modified scale (SEGAm).
SEGAm includes 13 items (coded from 0 to 2) to obtain a global score out of 26 points.
Patients with a score less than or equal to 8 are considered not fragile.
Patients with a score between 8 and 11 are considered fragile.
Patients with a score greater than or equal to 11 are considered very fragile.
|
Day 0
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 6, 2022
Primary Completion (Actual)
February 22, 2022
Study Completion (Actual)
February 22, 2022
Study Registration Dates
First Submitted
December 6, 2021
First Submitted That Met QC Criteria
December 6, 2021
First Posted (Actual)
December 20, 2021
Study Record Updates
Last Update Posted (Actual)
March 10, 2022
Last Update Submitted That Met QC Criteria
March 9, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-012-FRAIL-DOM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.